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Previous studies have demonstrated a common variant of the obesity and fat mass-related FTO gene, rs9939609, to be associated
with obesity, type 2 diabetes, and elevated blood pressure. We investigated whether the FTO SNP rs9939609 is associated with the
risk of preeclampsia (PE) in a Finnish study population. 485 women with prior PE and 449 women who had given birth after a
normotensive pregnancy were genotyped (TaqMan) for the SNP rs9939609. The prevalences of genotypes AA, AT, and TT were
15%, 53%, and 32%, respectively, among the PE cases, and 16%, 47%, and 37%, respectively, among the controls (P = 0.199).
We found no evidence of an association between the FTO SNP rs9939609 and PE. However, our cases were dominated by severe,
early-onset PE. Thus, we are unable to exclude an association with the milder, later-onset form of the disease in which the role of
maternal metabolic predisposition could be more signiﬁcant.
1.Introduction
Alongwiththeobesitypandemic,womenofreproductiveage
are gaining weight [1]. Overweight and obesity predispose
to various pregnancy complications, such as preeclampsia
(PE) [2]. PE is a potentially life-threatening syndrome of
hypertension, proteinuria, generalized vasoconstriction, and
platelet consumption, complicating 2–6% of ﬁrst pregnan-
cies [3]. Its exact pathogenesis remains unclear, but both
geneticandenvironmentalfactorsseemtoplayarole.Studies
have shown links between the pathologic characteristics of
the metabolic syndrome, gestational diabetes and type 2
diabetes (T2DM), and those of PE (e.g., obesity, hyperin-
sulinemia, hypertriglyceridemia, thrombotic and proinﬂam-
matory changes, endothelial dysfunction, and sympathetic
overactivity) [4–6]. Many of the metabolic abnormalities
appear to persist several years postpartum [7–10]. In line
with these ﬁndings, patients with prior PE seem to be at
elevated risk of developing impaired glucose tolerance or
T2DM in later life [11, 12].
Genome-wide association studies in several ethnic pop-
ulations have shown a common variant of the highly poly-
morphic obesity and fat mass-related FTO gene, rs9939609
(T/A), located on chromosome 16q2, to be associated with
obesity and T2DM [13, 14]. While the mechanisms of this
association are not known, the eﬀect of FTO variants on
the risk of T2DM is mediated by the eﬀect of FTO on
the body-mass index (BMI). Recent studies have revealed
linkages between FTO variants and gestational diabetes [15],
the polycystic ovary syndrome (PCOS) [16]a sw e l la s
the metabolic syndrome and hyperandrogenism in PCOS
women [17, 18]. The A-allele of rs9939689 has also been2 Journal of Pregnancy
associated with elevated blood pressure in Finnish women
andFrenchCanadians[19,20].AsPEislinkedtomanyofthe
above-mentioned conditions associated with FTO variants,
we decided to investigate whether the SNP rs9939609 is
associated with the risk of PE in a Finnish study population.
2.MaterialandMethods
We genotyped the FTO SNP rs9939609 in 485 Finnish
women with prior PE in a singleton pregnancy and 449
control women who had given birth after a normotensive
singleton pregnancy. The subjects came from three diﬀerent
studies described below. All subjects provided a written
informed consent, and all study protocols were approved
by the appropriate local ethical committees. In addition, the
approval of the Finnish Ministry of Social Aﬀairs and Health
was obtained for the population-based study (data set 1).
The diagnostic criteria of PE used are deﬁned below sep-
arately for each study. Systolic blood pressure ≥ 160mmHg
and/or diastolic blood pressure ≥ 110mmHg was classiﬁed
as severe PE. The criteria for severe PE used in this study
do not include the severity of proteinuria as quantitative
measurements of proteinuria were not available for all cases.
Prepregnancy weight and height were obtained from the
antenatal care records, where they are in most cases recorded
as reported by the mother at the ﬁrst maternity clinic visit,
usually before 12 weeks of gestation. Body mass index (BMI)
was deﬁned as the prepregnancy weight in kilograms divided
by height in meters squared (kg/m2). BMI ≥ 25kg/m2
was classiﬁed as overweight and BMI ≥ 30kg/m2 as obese.
Small-for-gestational age (SGA) was deﬁned as relative birth
weight under −2.0 SD units (Z score) according to Finnish
standards [21].
2.1. Data Set 1: Finnish Population-Based Preeclampsia Study.
The cases and controls for the population-based data set
were identiﬁed by combining two national registers [22].
In Finland, pregnant women are registered in the National
Register of Blood Group and Blood Group Antibodies of
Pregnant Women at the Finnish Red Cross Blood Service,
fromwhich100.000 consecutivepregnant women wereiden-
tiﬁed during 1997-1998. Of these, 1084 had an International
Classiﬁcation of Diseases (ICD-10) code for PE or eclampsia
in the National Hospital Discharge Register maintained by
the National Research and Development Centre for Welfare
and Health. First, 665 women with PE diagnosis were invited
to the study, and 411 (62%) participated. After checking the
case records and excluding multiple pregnancies, 226 cases
with singleton pregnancies fulﬁlled the criteria for PE. In
addition to PE patients, a random sample of women without
pregnancy complications (n = 1930) were invited to the
study, and 843 (44%) participated. Of these, 346 women
with singleton full-term pregnancies without hypertensive
complications, matched as closely as possible with the cases
fortheprovinceofresidence,parity,andmaternalage,served
as controls in this study. All participants were of Finnish
ethnic origin, gave blood samples for the study, and ﬁlled
out questionnaires to supplement the data obtained from
medical records.
PE was deﬁned as systolic blood pressure ≥ 140mmHg
and diastolic blood pressure ≥ 90mmHg with new-onset
proteinuria (0.3g/l or ≥0.5g/24 hours or dipstick ≥ +
representing values ≥0.3g/l) after 20 weeks of gestation in
a previously normotensive woman (slightly modiﬁed from
ACOG criteria) [22, 23]. The highest blood pressure values
were recorded.
2.2. Data Set 2: Southern Finland Preeclampsia Study. Us-
ing the discharge records, we identiﬁed women who had
developed severe PE and given birth in Helsinki University
Central Hospital between January 1988 and April 1998 [24].
Patients with multiple pregnancies were excluded. Blood
samples were collected between January 1997 and April
1998 after the index pregnancy. During the same period,
blood samples were collected from control subjects with
singleton deliveries in the same hospital after uncomplicated
pregnancies. In total, 129 preeclamptic women and 103
normotensive healthy controls with no pregnancy compli-
cations were recruited. Among the PE cases, 102 women
had a systolic blood pressure ≥160mmHg and/or a diastolic
bloodpressure ≥110mmHg,and61patientshadproteinuria
of at least 5g per 24-hour urine collection. All subjects
were of Finnish ethnic origin, lived in southern Finland,
and had been healthy before their ﬁrst pregnancy, without
evidence of renal or autoimmune diseases. At 12 weeks
postpartum, all women were normotensive, and proteinuria
had disappeared.
The diagnostic criteria of PE used were systolic blood
pressure ≥ 140mmHg and diastolic blood pressure ≥
90mmHg with new-onset proteinuria (≥0.3g/24 hours)
after 20 weeks of gestation in a previously normotensive
woman [24]. The blood pressure was conﬁrmed by two
measurements taken at least 6 hours apart.
2.3. Data Set 3: Eastern Finland Preeclampsia Study. The
samples of this data set were collected retrospectively from
women with prior PE when primiparous who delivered
at Kuopio University Hospital between January 1994 and
December 1998 [25]. PE patients were identiﬁed from the
Birth Registry of the City of Kuopio, contacted by telephone,
and asked to participate in the study and sign a consent
form. Patients with multiple pregnancies were excluded. In
total, samples obtained from 130 women with prior PE in a
singleton pregnancy were analyzed.
In this study, PE was deﬁned as the development
of hypertension and new-onset proteinuria (≥300mg of
urinary protein per 24 hours). Hypertension was deﬁned as
≥140mmHg systolic and/or ≥90mmHg diastolic pressure,
when measured on two consecutive occasions at least 24
hours apart [26]. Women with essential hypertension were
excluded from the study.
2.4. SNP Genotyping. The FTO SNP (rs9939609) was
genotyped using an ABI TaqMan allele discrimination
predesigned SNP genotyping assay (Applied Biosystems).Journal of Pregnancy 3
Polymerase chain reaction (PCR) ampliﬁcation was carried
out according to the manufacturer’s instructions. An ABI
7500 real-time thermocycler (Applied Biosystems) was used
to perform plate reading. Automated allele calling was
performed by allelic discrimination plots using Applied
Biosystems 7500/7500 fast real-time PCR Software v.2.0.
2.5. Statistical Analyses. The Hardy-Weinberg equilibrium
calculator of the Genetic Online Encyclopedia (http://www
.oege.org/software/hardy-weinberg.shtml)w a su s e dt ot e s t
for deviations in genotype distributions from the Hardy-
Weinbergequilibrium.Poweranalysiswasperformedassum-
ing a PE prevalence of 3%, high-risk allele (A) frequency of
0.3272 [27], genotypic relative risk of 1.5 for AT, and 2.0 for
AA. With these assumptions, a sample size of 263 PE cases
was estimated to result in a power >0.80 when α<0.05.
Diﬀerences of the background characteristics between
cases and controls were analyzed using the Student’s t-test or
the Mann-Whitney test (continuous variables) and the Chi-
square test or the Fisher’s exact test (frequencies for discrete
variables). Of the continuous variables, the BMI had a right-
skewed distribution, and the birth weight in grams had a
left-skewed distribution. The BMI was log transformed to
attainnormalityforthelogisticregressionanalysesofTable3.
Diﬀerences in the frequencies of genotypes and alleles
were analyzed using the Chi-square test. Logistic regression
analysis was used for the calculation of crude and adjusted
odds ratios (OR). Linear regression analysis was used to
determine the association of continuous variables with the
risk allele. One-way analysis of variance (ANOVA) and the
Bonferroni post hoc test were used to compare the means of
continuous variables among the diﬀerent genotype groups
and data sets. P value < 0.05 was considered statistically
signiﬁcant in all analyses. The statistical software used was
PASW Statistics 18.0 and Prism for Windows, version 4.03,
GrapPad Software Inc, La Jolla, Calif, USA.
3. Results
3.1. Characteristics of the Study Subjects. The combined
background characteristics of the three study populations
used in this study are presented in Table 1. There was
no signiﬁcant diﬀerence in the mean age of PE cases and
controls. Expectably, the cases had a higher mean BMI
than the controls although the diﬀerence was statistically
signiﬁcant only among the primipara. In addition, the cases
delivered earlier and their infants had a lower birth weight.
Pregestational and gestational diabetes were slightly more
common among the primiparous PE cases than among the
primiparous control women.
When the PE cases of the three data sets were studied
separately, signiﬁcant diﬀerences in the background charac-
teristics and risk factors were found between the data sets.
The mean BMI values among the PE cases in data sets 1, 2,
and 3 were 24.3kg/m2, 22.4kg/m2, and 24.8kg/m2,r e s p e c -
tively, with the diﬀerence between data set 2 and the other
twodatasetsbeingstatisticallysigniﬁcant(P<0.001).Indata
sets 1 and 2, the mean systolic blood pressure used to deﬁne
PE in cases was similar, 170.2mmHg and 170.9mmHg,
respectively, but in data set 3, it was signiﬁcantly lower,
161.0mmHg (P < 0.001). Correspondingly, the mean dias-
tolic blood pressure values used to deﬁne PE in data sets
1 and 2 were 106.1mmHg and 107.2mmHg, but in data
set 3, the mean was 102.9mmHg (P = 0.016 and P = 0.002
for data set 3 versus data sets 1 and 2, resp.). The mean
gestational age at delivery was higher among the PE cases of
dataset1(36.6weeksgestation)comparedwiththoseofdata
sets 2 (34.4 weeks gestation) and 3 (35.1 weeks gestation) (P
< 0.001 and P = 0.001, resp.). Also the relative birth weight
was higher among the oﬀspring of cases of data set 1 (−1,0
SD units) compared with those of data set 2 (−1.6 SD units)
and data set 3 (−1.4 SD units) (P = 0.001 and 0.017, resp.).
3.2.RiskFactorsofPreeclampsia. Well-establishedriskfactors
of PE such as BMI (odds ratio [OR] for each kg/m2
increase in BMI = 1.07; 95% CI: 1.04, 1.11; P < 0.001),
primiparity (OR = 1.37; 95% CI: 1.05, 1.79; P = 0.020), and
pregestational diabetes (OR = 6.16; 95% CI: 1.38, 27.4; P =
0.017) were associated PE also in this study population when
all three data sets were combined. When the data sets were
analyzed separately, prepregnancy BMI was associated with
PE (OR = 1.11; 95% CI: 1.06–1.15; P < 0.001) and severe
PE deﬁned by hypertensive criteria only (OR: 1.10; 95% CI:
1.06–1.16; P < 0.001) in data set 1 but not in data set 2
(OR = 0.95; 95% CI: 0.87, 1.03; P = 0.172; and OR = 0.963;
95% CI: 0.89, 1.05; P = 0.963, resp.).
Overall, 17.9% of all study subjects were overweight and
7.5% were obese. In data sets 1, 2, and 3, the percentages of
overweight and obese patients were 19.1% and 7.0%, 12.1%
and 4.3%, and 23.1% and 15.4%, respectively. No diﬀerence
in the frequency of overweight or obesity was found between
subjects homozygous for the A-allele of rs9939609 and those
homozygous for the T-allele (P = 0.406 and P = 0.134,
resp.).Intheentirestudypopulation,eachadditionalA-allele
corresponded to an increase in BMI of 0.145 kg/m2, but the
resultwasstatisticallynonsigniﬁcant(95%CI: −0.245,0.535,
P = 0.446). Among the cases and the controls, the BMI eﬀect
peroneA-allelewas0.082kg/m2 (P =0.791,95%CI: −0.526,
0.690) and 0.025kg/m2 (P = 0.923, 95% CI: −0.474, 0.523),
respectively. In data sets 1, 2, and 3, the BMI-changes per
each additional A-allele were 0.197 (95% CI: −0.291, 0.685;
P = 0.427), −0.412 (95% CI: −1.043, 0.219, P = 0.200), and
1.409 (95% CI: −0.034, 2.852; P = 0.056), respectively. The
mean BMI for the genotypes TT, AT, and AA were 23.2, 23.5,
and 23.5 for data set 1, 23.1, 22.5, and 22.3 for data set 2
and 24.2, 24.9, and 27.5 for data set 3, respectively, with all
diﬀerences between groups being statistically nonsigniﬁcant.
3.3. rs9939609 and Preeclampsia. The rs9939609 genotypes
and allele frequencies among the PE cases and controls are
presented in Table 2. The genotype distributions did not
deviate from the Hardy-Weinberg equilibrium among the
cases or the controls. No evidence of an association between
SNP rs9939609 of FTO and PE was found in this study.
The prevalences of genotypes AA, AT, and TT were 15%,
53%, and 32%, respectively, among the PE cases, and 16%,4 Journal of Pregnancy
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Table 2: FTO SNP rs9939609 genotypes and allele counts among the Finnish preeclampsia patients and control subjects from data sets 1, 2,
and 3.
Preeclampsia Controls P∗∗
Primiparous Multiparous Combined Primiparous Multiparous Combined Primiparous Multiparous Combined
n = 321 n = 164 n = 485 n = 264 n = 185 n = 449
Genotypes
AA 51 20 71 39 30 69
AT 159 92 251 118 92 210
TT 106 48 154 104 63 167 0.291 0.328 0.199
N/A∗ 54930 3
Alleles (frequency)
A 261 (0.41) 132 (0.41) 393 (0.41) 196 (0.38) 152 (0.41) 348 (0.39)
T 371 (0.59) 188 (0.59) 559 (0.59) 326 (0.62) 218 (0.59) 544 (0.61) 0.195 0.964 0.321
∗Genotyping failed.
∗∗Chi-square test.
Table 3: The odds ratios (95% CI) for preeclampsia (PE). Severe PE and small-for-gestational age (SGA) associated with maternal FTO SNP
rs9939609 AA and AT genotypes as well as with each additional A allele (unadjusted and adjusted) in a Finnish study population.
OR (95% CI) for outcome
Covariates PE Severe PE∗∗ SGA
TT reference reference reference
AT∗ 1.30 (0.97.1.72) 1.31 (0.95.1.79) 1.05 (0.70.1.57)
AA∗ 1.12 (0.75.1.66) 0.98 (0.62.1.53) 0.83 (0.45.1.50)
Per A-allele, unadjusted∗ 1.10 (0.91.1.33) 1.05 (0.85.1.30) 0.94 (0.72.1.24)
Per A-allele, adjusted for log-transformed BMI∗ 1.09 (0.89.1.32) 1.04 (0.84.1.28) 0.91 (0.69.1.21)
Per A-allele, adjusted for log-transformed BMI, age and diabetes∗ 1.09 (0.90.1.32) 1.03 (0.83.1.28) 0.90 (0.68.1.20)
∗Binary logistic regression analysis.
∗∗Nonsevere PE cases excluded.
47%, and 37%, respectively, among the controls (P = 0.199).
The crude and adjusted odds ratios for the association of
FTO with PE, severe PE, and the delivery of a small-for-
gestational-age (SGA) infant are presented in Table 3.
4. Discussion
Although overweight is a major risk factor of pregnancy-
induced hypertension and PE [2], we were unable to demon-
strate an association between the obesity-predisposing
rs9939609 of FTO and PE in this study. To the best of our
knowledge, no reports on this subject have been published
previously.
The study population used in this study can be con-
sidered fairly representative of the Finnish population as
it is composed of a population-based sample as well as
subjects recruited from hospitals with geographically based
catchment areas in both Eastern and Southern Finland. The
A-allele frequency among this study population is somewhat
higher than that reported by another Finnish study [27]b u t
in line with the frequency demonstrated in other European
populations [28].
One of the weaknesses of the data sets used in this
study was the lack of information on lifestyle factors, which
could have inﬂuenced the association of rs9939609 with
BMI. Past studies regarding the interaction of physical
activity and the eﬀect of the FTO genotype on BMI have
been somewhat conﬂicting. Karasawa et al. [29] studied the
eﬀect of energy expenditure for moderate to high-intensity
physical activity on the association of rs9939609 of the FTO
with obesity. The group found BMI to be signiﬁcantly higher
and obesity more frequent in the group with genotype AA
and low physical activity, but not in the group with genotype
AA and high physical activity. Other researchers have also
reported the eﬀect of FTO on obesity to be exacerbated
by low physical activity [30–33]. On the contrary, a study
by Jonsson et al. [34] with a sample of 15925 Swedish
and 2511 Finnish nondiabetic adults did not support the
notion that physical activity modiﬁes the eﬀects of the FTO
rs9939609 variant on obesity. Furthermore, Lappalainen et
al. [35] found no association between FTO variant and
the magnitude of weight reduction achieved by a long-
termlifestyleinterventionintheFinnishDiabetesPrevention
Study (DPS) among middle-aged subjects with impaired
glucose tolerance.
The study population consisted entirely of women of
reproductive age. However, the lack of male study subjects
should not be behind the lack of BMI association as previous
studies have consistently shown the A-allele of rs9939609
to predispose to obesity independent of sex [13]. The few6 Journal of Pregnancy
studies that have reported sex diﬀerences have demonstrated
astrongereﬀectamongwomen[35,36].Itisunlikelythatthe
mean age of the study populations would conceal the BMI-
eﬀect because the association of the rs9939609 of FTO with
BMI has been clearly shown among both children and adults
[13, 28]. Hardy et al. [37] have, however, demonstrated the
eﬀect to peak at 20 years and then weaken with progressing
age.
The present study population was relatively lean, with
the mean BMIs ranging from 22.4 to 24.8 in the three
data sets analysed. However, the prepregnancy body weight
was self-reported by the study subjects and thus might be
somewhat underreported. Nevertheless, the leanness of the
study population might be one factor contributing to the
lack of association of FTO with BMI in this study. This is
supported by the fact that the FTO-BMI eﬀect per one A-
allele was the largest and approached statistical signiﬁcance
among the subjects of data set 3, which included more
overweight and obese subjects than the other data sets. The
results of Jacobsson et al. [33] also suggested that the impact
ofFTOonobesitymaybelessprominentinleanpopulations.
On the other hand, the FTO-BMIassociation was clear in the
ALSPAC study population, which was composed of women
of reproductive age with a mean BMI comparable to the one
reported in the present study [28].
The diﬀerences in the background characteristics of the
three PE data sets could explain why no association was
demonstrated between the rs9939609 of FTO and BMI or PE
in this study. The PE cases in data set 2 suﬀered predomi-
nantly from the severe, earlier-onset form of PE with high
proteinuria, whereas in data sets 1 and 3, the severity of PE
among the cases varied. In data set 2, the cases were the lean-
est, BMI was not associated with an increased risk of PE, and
the gestational age at delivery was the lowest. This is in line
with the hypothesis that the early-onset PE is characterized
byabnormalplacentationandastrongergeneticcomponent,
while the role of maternal metabolic predisposition is more
signiﬁcant in the late-onset form of the disease [38].
5. Conclusions
We found no evidence of an association between the fat-
mass-associated SNP rs9939609 and PE. It is possible that
risk factors other than obesity dominate among patients
manifesting severe, early-onset PE compared to those with
a milder, later-onset form of the disease. Our cases were
dominated by the more severe end of the disease spectrum,
and therefore we are unable to exclude an association in
particular with the less severe, later-onset forms of the
disease. The possible association of the fat-mass-associated
SNP rs9939609 and PE should be further investigated with
larger sample sizes and with possibilities of stratifying the
sample according to the degree of severity and the gestation
weeks at the onset of the disease.
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